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ABSTRACT

KEREN LEVIEL: Investigation of Polymorphisms in Schizophrenia Relevant Genes 

(Under the direction of Patrick F. Sullivan) 

Schizophrenia is a severe, debilitating, and complex disease. It is characterized by delusions, 
hallucinations, disorganized speech, and grossly disorganized or catatonic behavior. As a 
complex disease, schizophrenia is thought to be caused by many genes. In addition the 
etiology is thought to be heterogeneous across the population of persons suffering from 
schizophrenia. In an attempt to dissect the heterogeneity of the disease, and investigate the 
role of candidate genes associated with schizophrenia, several studies were completed. The 
first was a case only association study of neurocognition and COMT, a candidate gene for 
schizophrenia. This is the largest study of its kind to date. The second study addresses the 
possibility of predisposition due to differential expression of candidate genes. In this study 
expression of another candidate gene PRODH was assessed. Together these studies aimed at 
investigating the polymorphisms of candidate genes for schizophrenia. 
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Chapter 1 
Introduction 
 Schizophrenia is a severe mental illness.  The current criteria for the diagnosis of 
schizophrenia according to the DSM-IV (American Psychiatric Association 1994) is    
A. Characteristic symptoms: Two (or more) of the following, each present for a 
significant portion of time during a 1-month period (or less if successfully treated):  
1. delusions  
2. hallucinations  
3. disorganized speech (e.g., frequent derailment or incoherence)  
4. grossly disorganized or catatonic behavior  
5. negative symptoms, i.e., affective flattening, alogia, or avolition  
Note: Only one Criterion A symptom is required if delusions are bizarre or 
hallucinations consist of a voice keeping up a running commentary on the person's 
behavior or thoughts, or two or more voices conversing with each other. 
B. Social/occupational dysfunction: For a significant portion of the time since the onset 
of the disturbance, one or more major areas of functioning such as work, 
interpersonal relations, or self-care are markedly below the level achieved prior to the 
onset (or when the onset is in childhood or adolescence, failure to achieve expected 
level of interpersonal, academic, or occupational achievement).  
C. Duration: Continuous signs of the disturbance persist for at least 6 months. This 6-
month period must include at least 1 month of symptoms (or less if successfully 
treated) that meet Criterion A (i.e., active-phase symptoms) and may include periods 
of prodromal or residual symptoms. During these prodromal or residual periods, the 
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signs of the disturbance may be manifested by only negative symptoms or two or 
more symptoms listed in Criterion A present in an attenuated form (e.g., odd beliefs, 
unusual perceptual experiences).  
D. Schizoaffective and Mood Disorder exclusion: Schizoaffective Disorder and Mood 
Disorder With Psychotic Features have been ruled out because either (1) no Major 
Depressive, Manic, or Mixed Episodes have occurred concurrently with the active-
phase symptoms; or (2) if mood episodes have occurred during active-phase 
symptoms, their total duration has been brief relative to the duration of the active and 
residual periods.  
E. Substance/general medical condition exclusion: The disturbance is not due to the 
direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a 
general medical condition.  
F. Relationship to a Pervasive Developmental Disorder: If there is a history of Autistic 
Disorder or another Pervasive Developmental Disorder, the additional diagnosis of 
Schizophrenia is made only if prominent delusions or hallucinations are also present 
for at least a month (or less if successfully treated). 
 
It is widely suspected that the etiology of schizophrenia is heterogeneous and the 
proportion of genetic and or environmental causes of their illness is dissimilar both within 
and across populations.  This heterogenic property makes it very difficult to study 
schizophrenia, a characteristic of the disease that will be discussed further in Chapter 3 of 
this thesis.  The lifetime prevalence of schizophrenia in the U.S. and in most countries is 
about 1% (Jablensky, Sartorius et al. 1992), with a few populations such as the Palau Islands 
a Micronesian population isolate which have an increased prevalence of 2% (Camp, 
Neuhausen et al. 2001).   
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 Generally the onset of schizophrenia is in early adulthood, between 15 and 25 years 
of age.  The average age of onset tends to be higher for females than for males.  In 2005, it 
was estimated that the societal cost of schizophrenia in 2002 was $62.7 billion of which 
$32.4 billion was mainly due to unemployment (Wu, Birnbaum et al. 2005).  Thus, any 
information which leads to a reduction in the amount of time a person who suffers from 
schizophrenia spends unemployed, would be beneficial not only to the patient and his family, 
but also to the U.S. economy.   
 Several genetic epidemiological studies have shown that schizophrenia has both a 
genetic and an environmental component.  In a 1998 review of family and twin studies 
published between 1920 and 1987, Moldin (Moldin and Gottesman 1997) found the average 
concordance rate for schizophrenia among monozygotic twins to be 46% even when reared 
by different families, while the average concordance rate for dizigotic twins was only 14%.  
In addition, risk of schizophrenia increases with increasing biological relatedness to a person 
suffering from schizophrenia.  This means that third-degree relatives have a lower risk than 
second-degree relatives who have a lower risk than first-degree relatives who have a lower 
risk than monozygotic twins.  When biological children of a parent with schizophrenia are 
adopted, they develop schizophrenia or other related disorders at the increased rate seen in 
first-degree relatives rather than that of the general population (Kety 1988; Kety, Wender et 
al. 1994).  A recent meta-analysis by Sullivan et al which analyzed all published twin studies 
of schizophrenia, reported that schizophrenia, while heterogeneous, develops as a result of 
both genetics and environment (Sullivan, Kendler et al. 2003). Clearly genetics plays a role 
in schizophrenia, but it does not act alone, if it did monozygotic twins would be 100% 
concordant rather than the reported 46-48%.  This means that other factors such as 
4 
environment, X inactivation, or methylation differences may be involved.  Since it is quite 
clear that factors other than genetics are involved, when considering a genetic study, 
heritability is important.  There have been several different estimates of the heritability of 
schizophrenia ranging from 80 to 86 percent (Farmer, McGuffin et al. 1987; Onstad, Skre et 
al. 1991; Cannon, Kaprio et al. 1998).  The best available estimate is 81% (Sullivan, Kendler 
et al. 2003).  While the reported heritability for schizophrenia is high, it cannot be completely 
understood without taking environmental factors into account.  
 Schizophrenia is a complex trait (Sullivan, Kendler et al. 2003), for which there have 
been many attempts to elucidate its etiology.  Attempts include studies of cytogenetics, 
epigenetics, linkage, association, putative biomarkers, and multiple epidemiological risk 
factors (e.g., seasonal birth effects, exposures in utero, and obstetric complications).   
One of the major genetic findings in schizophrenia is its connection with velo-cardio-
facial syndrome (VCFS).  VCFS is caused by a deletion of a 1.5-3 megabase section of 
chromosome 22q11.  Persons suffering from VCFS have a 1 in 4 chance of developing 
schizophrenia, which is quite higher than the general population risk of about 1% (Saha, 
Chant et al. 2005).  In addition, approximately 1% of patients with schizophrenia possess the 
VCFS deletion (Horowitz, Shifman et al. 2005).  The set of genes deleted in this syndrome is 
of great interest to the study of schizophrenia.  In addition, as previously mentioned other 
studies such as association and linkage studies have also lead to a large number of candidate 
genes for the study of schizophrenia.  After reviewing recent meta analyses (Harrison and 
Weinberger 2005) and other research available, a list of candidate genes (Sullivan 2005) for 
schizophrenia was generated for the purpose of the work which is to follow.  The following 
genes were included in that list: AKT1, catechol-O-methyltransferase (COMT), disrupted in 
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schizophrenia 1 & 2 (DISC 1 & 2), dopamine transporter (SLC6A3, DAT), dopamine 
receptor type 3 (DRD3), dysbindin (DTNBP1), neuregulin (NRG1), proline dehydrogenase 1 
(PRODH), regulator of G-protein signaling 4 (RGS4), and serotonin transporter (SLC6A4).  
Two of these genes (COMT and PRODH) were investigated in the studies reported in this 
thesis. 
 This body of work includes three different investigations aimed to further understand 
the potential importance of polymorphisms in the 22q11 genes COMT and PRODH.  Both 
PRODH and COMT have been linked to schizophrenia.  COMT has been shown to be 
strongly associated with schizophrenia, while to date only a weak association to PRODH has 
been reported (Harrison and Weinberger 2005).  The first investigation (Chapter 2), is an 
analysis of a whole genome amplification method.  The goal of this study is to determine if 
the method is accurate.  The amplification method could potentially be used to amplify 
human DNA samples for which very small quantities are available.  Many potential control 
groups for the association study that follows have very small amounts of DNA available.  
Hence, an accurate method for whole genome amplification would allow for flexibility in 
finding a control group.  The next study (Chapter 3) is aimed at investigating polymorphisms 
of COMT in relation to neurocognition in persons with schizophrenia.  Studying 
neurocognition as an endophenotype for schizophrenia will allow us to dissect the 
heterogeneity of the disease.  The final investigation (Chapter 4) focuses on the expression of 
the candidate genes.  It examines the hypothesis that differences in expression of certain 
genes may lead to predisposition to disease.  So, when considering the variations in the set of 
candidate genes, expression levels are also relevant.  The aim of this chapter is to establish 
and test the tools necessary to study differential allelic expression (DAE) of the candidate 
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genes in mice, and attempt to determine if PRODH exhibits DAE.  Together these three 
studies set the ground work for further investigation of the polymorphisms of the candidate 
genes for schizophrenia, and offer some insight into the polymorphisms of COMT. 
Chapter 2 
Genotyping Accuracy for Whole-Genome Amplification of DNA 
from Buccal Epithelial Cells 
Introduction 
Many population and twin registries have collected DNA via buccal epithelial cell brush or 
mouthwash protocols. The choice of this method of DNA collection was due to its low 
subject burden and relatively small expense (10-20% of the cost of collection of a peripheral 
venous sample). However, the disadvantage of buccal DNA collection is the lesser quantity 
and poorer quality of DNA in comparison to DNA derived from lymphocytes. Many 
investigators now wish to genotype existing samples for a large number of markers and the 
DNA mass required for these genotyping reactions often exceeds the DNA yield of most 
buccal DNA extraction protocols. The control samples for our association study come from 
the Add Health study, for which DNA was extracted from buccal cells, and hence not much 
DNA is available. 
Recently, several whole genome amplification protocols have been described using 
rolling circle amplification with Φ29 DNA polymerase (Dean, Hosono et al. 2002; Nelson, Cai 
et al. 2002). These approaches appear to be accurate and robust for DNA from lymphocytes 
(Hosono, Faruqi et al. 2003; Tranah, Lescault et al. 2003). There are no published data 
however on how these methods perform with buccal-derived DNA samples.  The goal of this 
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study was to compare the accuracy of whole genome amplification of DNA obtained from 
buccal samples in relation to lymphocyte DNA from the same individuals. 
Methods 
 Paired DNA samples from 30 individuals (DNA from blood versus amplified buccal 
DNA) were compared for five microsatellites, two variable number of tandem repeats 
(VNTRs), and 12 SNPs. All SNPs and one VNTR were genotyped twice to assess replication 
error.  Thirty volunteers ascertained by convenience sampling donated both blood and buccal 
samples. Genomic DNA was extracted from approximately eight mL of whole blood using a 
Puregene DNA Purifcation Kit for whole blood samples (Gentra Systems, Minneapolis, 
MN). DNA from fresh buccal cells was extracted from three sterile cytology brushes using 
the Puregene Genomic DNA Purification Kit for buccal samples (Gentra Systems, 
Minneapolis, MN). Extracted buccal cell DNA (800-1000 ng total yield) was amplified using 
the GenomiPhi DNA Amplification Kit (Amersham Biosciences) via the manufacturer’s 
protocol and using ~20 ng of DNA to seed the reaction.  
Blood and amplified buccal samples from each of the 30 volunteers were genotyped for 
five microsatellites, two VNTRs, and 12 SNPs. These markers were scattered across the 
genome, and most are pertinent to neuropsychiatric disorders. The five microsatellites were 
D10S526, D5S592, FES/FPS, vWA31, and D22S417. The two VNTRs were located in the 
dopamine transporter (SLC6A3, 3’ DATVNTR) (Kang, Palmatier et al. 1999) and serotonin 
transporter (SLC6A4, 5-HTTLPR) (Lesch, Bengel et al. 1996). The SNPs were from dbSNP 
(rs1042713, rs6277, rs6265, rs4680, rs2619539, rs1801282, and rs1801133), ABI “Assay-on-
Demand” library (C_7586657, C_8878813, C_304219, and C_2270166), and deCODE 
(NRG225133) (Stefansson, Sigurdsson et al. 2002).  
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 All PCR reactions were completed on an MJ Research PTC-200 DNA Engine (Global 
Medical Instrumentation, Inc, Ramsey, MN). Microsatellite and VNTR markers were run on 
an ABI 3730 DNA Analyzer (Applied Biosystems, Foster City, CA). ABI GeneMapper 
(v3.5) was used for semi-automated genotype calls with verification by an experienced 
operator and pre-established quality control procedures. SNPs were genotyped using TaqMan 
pre-developed assay reagents for allelic discrimination and run on an ABI Prism 7900HT 
Sequence Detection System. Genotypes that could not be easily determined by an 
experienced operator were termed “no-calls”.  
 This study was reviewed and approved by the UNC Medical IRB. All subjects 
provided written informed consent. All samples were anonymized following collection.  
 
Results 
We considered three metrics by which to gauge genotyping accuracy (Table 2.1): no-
call proportions, reproducibility (test-retest), and concordance (blood versus amplified buccal 
DNA) (Oliphant, Barker et al. 2002). No-calls were considered missing data for all 
reproducibility and concordance calculations. 
No-Call Proportions. For SNPs, the overall no-call proportions were 0.28% (2/720) 
for DNA from lymphocytes and 0.69% (n=5/720) for DNA from buccal cells (Fisher’s Exact 
Test p=0.45). For the remaining genotypes, the overall no-call proportions were 1.25% 
(3/240) for DNA from lymphocytes and 2.50% (n=6/240) for DNA from buccal cells 
(Fisher’s Exact Test p=0.50). No individual sample was consistently not called.  
Reproducibility was determined by repeating genotyping for 12 SNPS and one VNTR 
(DATVNTR). Genotype calling was blind to previous results. SNP reproducibility was 100% 
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(358/358) for DNA from blood and 99.15% (352/355) for amplified buccal DNA (Fisher’s 
Exact Test p=0.12). For the one VNTR, reproducibility was 100% for DNA from blood 
(29/29) and amplified buccal DNA (27/27) (Fisher’s Exact Test p=1).  
Concordance was assessed by pairwise comparison of blood versus amplified buccal 
DNA from the same subjects. For the 12 SNPs, the concordance was 99.58% (710/713). For 
the remaining markers, concordance was 100% (232/232).  
 
Discussion 
Our results suggest that whole genome amplification of buccal DNA samples via a 
Φ29 DNA polymerase/rolling circle method produces genotypes that are of comparable 
quality to those from genomic DNA from lymphocytes. Specifically, for 12 SNPs, five 
microsatellites, and two VNTRs, the no-call proportions and reproducibility were not 
significantly different for lymphocyte and amplified buccal DNA. In addition, the pairwise 
concordance for blood and amplified buccal samples was very high.  
We thought it reasonable to consider no-call genotypes as missing for two reasons. 
First, inspection of the dataset strongly suggested that these were missing at random with 
respect to the individual DNA samples. Second, these no-calls can generally be resolved with 
additional genotyping.  
These results do not remove the necessity to evaluate the adequacy of buccal whole 
genome amplification for every marker assessed. For example, markers requiring long PCR 
may be more likely to fail on buccal DNA (Roberts, Joyce et al. 2000). Moreover, even if 
whole genome amplification works well on average across the genome, there are likely to be 
discrete regions or markers for which it works far less well.  
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However, if investigators use appropriate experimental and design precautions, our results 
suggest that Φ29 DNA polymerase whole genome amplification can be used to increase the 
numbers of markers that can be genotyped on DNA from buccal samples collected from twin 
and other large population registries. 
 This is a slightly modified version of a published manuscript (Leviel, Olarte et al. 
2004).  All statistical analysis was performed by Patrick F. Sullivan.  I gathered subjects, 
collected samples, performed the amplifications, and completed the genotyping. 
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Table 2.1:  Comparison of genotyping accuracy between lymphocyte and amplified buccal 
DNA. 
Metric SNPs Microsatellites/VNTRs 
 Lymphocyte Buccal Lymphocyte Buccal 
Percent no 
calls 
0.28% 0.69% 1.25% 2.50% 
Reproducibility
1 
100% 99.15% 100% 100% 
Concordance 99.58% 100% 
1Microsatellite/VNTR reproducibility data includes DATVNTR only. 
Chapter 3 
Negative Association of COMT with Neurocognition in the CATIE 
Study 
Introduction 
 A promising but underutilized approach to studying schizophrenia has been the study 
of endophenotypes.  Endophenotypes are hypothesized to index disease liability more 
directly, as they are often quantitative traits and likely carry increased statistical power. This 
approach can also be viewed as a way to dissect the clinical heterogeneity of schizophrenia. 
 Neurocognitive functions are cognitive functions such a problem solving and 
language production which are closely related to regions of the nervous system.  
Neurocognition is a plausible endophenotype for schizophrenia (Gottesman and Gould 
2003). Indeed, neurocognitive dysfunction may be a defining feature of schizophrenia 
(Elvevag and Goldberg 2000) and cognitive impairment may be the best predictor of poor 
outcome (Green 1996). Following the Gottesman and Gould definition of an endophenotype 
(Gottesman and Gould 2003): a) Neurocognition is associated with schizophrenia in the 
general population with multiple domains >1 SD lower in individuals with schizophrenia 
than healthy controls (Saykin, Gur et al. 1991; Heinrichs and Zakzanis 1998). Patients with 
more severe cognitive deficits tend to have more negative symptoms (Manschreck, Maher et 
al. 1985; Addington, Addington et al. 1991; Strauss 1993), disorganization (Spitzer 1993), 
and adaptive dysfunction (Green 1996); b) Multiple domains of neurocognition are heritable 
– e.g., executive function (Swan and Carmelli 2002; Anokhin, Heath et al. 2003), working 
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memory (Cannon, Huttunen et al. 2000; Tuulio-Henriksson, Haukka et al. 2002), verbal 
learning and memory (Bouchard 1998; Tuulio-Henriksson, Haukka et al. 2002; Alfimova and 
Uvarova 2003), vigilance (Myles-Worsley and Coon 1997; Cannon, Huttunen et al. 2000), 
and processing speed (Swan, Carmelli et al. 1990; Swan and Carmelli 2002; Francks, Fisher 
et al. 2003; Luciano, Wright et al. 2004); c) Neurocognitive impairment is primarily 
independent of clinical state – present at first episode of psychosis, and often as severely 
impaired at first episode as in chronic schizophrenia (Hoff, Riordan et al. 1992; Saykin, 
Shtasel et al. 1994; Bilder, Goldman et al. 2000); d) Many domains of neurocognition co-
segregate with schizophrenia in families (Franke, Maier et al. 1992; Chen, Liu et al. 1998; 
Cannon, Huttunen et al. 2000; Michie, Kent et al. 2000; Egan, Goldberg et al. 2001); and e) 
Neurocognitive impairment is more common in unaffected family members than the general 
population (Cornblatt, Risch et al. 1988; Roxborough, Muir et al. 1993; Keefe, Silverman et 
al. 1994; Park, Holzman et al. 1995; Kremen, Faraone et al. 1998; Faraone, Seidman et al. 
1999; Laurent, Moreaud et al. 1999).  
 COMT (22q11.2) encodes a methyltransferase involved in dopamine metabolism. It 
affects prefrontal cortical function via modulation of neuronal dopamine activity in the 
prefrontal cortex and thereby affects neuronal response during working memory. A 
functional polymorphism (valine ? methionine (Val/Met)) has been identified and 
characterized (Chen, Lipska et al. 2004). Eagan and colleagues (Egan, Goldberg et al. 2001) 
reported an association between the more active Val allele and lower scores on the Wisconsin 
Card Sorting Test (WCST), which supports the idea that higher dopamine levels lead to 
better performance in executive functions. Among schizophrenia patients the association 
with the polymorphism has been very inconsistent (Harrison and Weinberger 2005) as is its 
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association with neurocognitive performance. Many of the recent publications which address 
the role of COMT in relation to neurocognition tend to have small sample sizes and usually 
focus only on the functional Val/Met polymorphism (Harrison and Weinberger 2005). This 
has been studied in a variety of populations including persons suffering from schizophrenia, 
their normal siblings, and persons suffering from ADHD (Bellgrove, Domschke et al. 2005; 
Harrison and Weinberger 2005; Turic, Williams et al. 2005). In one of these studies an 
association was found between the normal siblings of persons suffering from schizophrenia, 
but not in the patients (Rosa, Peralta et al. 2004). In addition Shifman et al., found a weak 
association with this allele, but a highly significant association with a COMT haplotype 
(Shifman, Bronstein et al. 2002). These types of results exemplify the need for a larger 
sample size in association studies, in addition to the need for more than one SNP to be 
genotyped.  
The goal of this investigation was to examine the associations of neurocognitive 
scores with 10 single nucleotide polymorphisms (SNPs) in or near the COMT gene 
(including the widely studied val158met SNP rs4680). The sample was drawn from the 
CATIE study and, to our knowledge, is the largest sample in which the molecular genetics of 
neurocognition has been investigated in schizophrenia.  
 
Methods 
Subjects. All subject were participants in the Clinical Antipsychotic Trials of 
Intervention Effectiveness project (CATIE, NIMH contract NO1 MH90001) which was 
conducted between January 2001 and December 2004. CATIE was a multi-phase randomized 
controlled trial of antipsychotic medications involving 1,460 persons with schizophrenia 
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followed for up to 18 months (Stroup, McEvoy et al. 2003; Lieberman, Stroup et al. 2005). 
The philosophy of the trial was to assess controlled treatment with antipsychotic drugs in a 
broad range of patients with schizophrenia under “real world” conditions. To maximize the 
representativeness of the sample, subjects were ascertained from a broad array of clinical 
settings scattered across the US (16 university clinics, 10 state mental health agencies, 7 
Veterans Affairs medical centers, 6 private nonprofit agencies, 4 private-practice sites, and 
14 mixed-system sites). 1,894 subjects were evaluated and 1,460 (77.0%) entered into 
CATIE. No subject was known to be related to any other subject. All subjects provided 
written informed consent (including an additional consent for genetic studies), and the full 
study protocol was reviewed by internal review boards at UNC and at participating study 
sites.  
Preliminary diagnoses were established by referring psychiatrists. Final study 
diagnoses were independently re-evaluated by CATIE personnel using the Structured 
Clinical Interview for DSM-IV (SCID) (First, Spitzer et al. 1994) using all available 
information (including psychiatric and general medical records) along with one or more 
subject interviews. Interviewers were experienced Master’s-level clinicians who were 
specifically trained to criterion via a standard protocol (First, Spitzer et al. 1994). Any 
diagnostic uncertainties were resolved via discussion with one of the CATIE senior 
clinicians. The DSM-IV (Association 1994) criteria for schizophrenia operationalized in the 
SCID include the explicit requirement for characteristic symptoms, significant dysfunction, 
and continuous signs of illness for ≥6 months. The SCID explicitly excludes clinically 
important phenocopies—e.g., mood disorders with psychotic features or symptoms resulting 
from the direct physiological effects of a substance (e.g., drugs of abuse or medications) or a 
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general medical condition. The definition is inherently rigorous and requires substantial 
evidence that consistently supports the diagnosis.  
Inclusion criteria were: definite diagnosis of schizophrenia (American Psychiatric 
Association 1994; First, Spitzer et al. 1994), age 18-65 years, clinical decision that oral 
medication is appropriate, adequate decisional capacity, and provision of written informed 
consent. Exclusion criteria – see Table 2 in Stroup et al. for a complete list (Stroup, McEvoy 
et al. 2003). Briefly, patients were excluded if they had received a diagnosis of 
schizoaffective disorder, mental retardation, or other cognitive disorders; had a history of 
serious adverse reactions to the proposed treatments; had had only one schizophrenic 
episode; had a history of treatment resistance, defined by the persistence of severe symptoms 
despite adequate trials of one of the proposed treatments or prior treatment with clozapine; 
were pregnant or breastfeeding; or had a serious and unstable medical condition. Individuals 
with psychoactive drug use disorders were included but only when there was positive 
evidence that schizophrenia was an independent diagnosis. The study was approved by the 
institutional review board at each site, and written informed consent was obtained from the 
patients or their legal guardians.  
DNA Sampling & Cell Line Establishment. Peripheral venous blood samples were 
obtained and sent to the Rutgers University Cell and DNA Repository (RUCDR) where cell 
lines were established via Epstein-Bar Virus transformation. Numerous quality control 
procedures are routine and the success rate for immortalization exceeds 99% 
(http://www.rucdr.org/quality_control.html). Sample DNA concentrations were quantified 
and normalized via the use of Picogreen dsDNA Quantitation Kits (Molecular Probes, 
Eugene, OR).  
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SNP Selection, Genotyping, & Quality Control. Ten SNPs were genotyped including 
rs6518592, rs2097603, rs2020917, rs737865, rs740603, rs740601, rs4680, rs4646316, 
rs165774, and rs165599.  rs6518592, rs2020917, and rs740603 were chosen for genotyping 
because they represent a HapMap haplotype in the Caucasian population, as were rs740601, 
rs4680, rs4646316, and rs165774.  Those SNPs were chosen in 2004 when this project was 
designed, and were chosen because they are tagging SNPs.  Three SNPs, including rs737865, 
rs4680 (part of another haplotype, and coding SNP), and rs165599 were chosen because of 
past research by Shifman et al, which found a significant association of this haplotype with 
schizophrenia.  The last SNP rs740603, was chosen because of it’s location in the promoter 
region of the gene.  In all these represent 2 HapMap haplotypes (release #11, 9/04), a 
haplotype previously reported by Shifman et al., and an additional promoter SNP.  
Representing the largest number of SNPs genotyped in any COMT study. 
We used TaqMan 5’ exonuclease assays (Livak 1999; Chen and Sullivan 2003) to genotype 
these 10 SNPs with probes and primers designed and supplied by Applied Biosystems 
(Foster City, CA). SNP markers were genotyped in a 384-well format. Each well contained 
5.0 ng of genomic DNA, two allele-specific fluorescent probes, and ABI TaqMan Universal 
Master Mix without UNG. The total reaction volume was 5 µL with PCR primer 
concentrations of 900 nM and TaqMan MGB-probe concentrations of 200 nM. PCR 
thermocycling conditions were: 95° C for 10 minutes, followed by 50 cycles of 95° C for 15 
seconds and 60° C for 1 minute, with a final incubation at 25° C (PE 9700, ABI). 
Fluorescence intensities were read by an ABI 7900HT. Automated allele calls were made 
with SDS Data Collection software with all allele calls reviewed by an experienced operator 
according to protocol. To pass quality control, we required that each plate have: no-call rates 
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≤5.0%, a random pattern of no-calls, and all genotypes in Hardy-Weinberg equilibrium 
(HWE) when stratified by inferred ancestry. The overall no-call percentage was 1.3% 
(82/6,336). Agreement between 48 duplicate samples per SNP was 100%. Genotyping was 
conducted blind to all clinical data.  
Neurocognitive Phenotypes. Analyses in this report are from the CATIE baseline 
dataset. The construction, implementation, and analyses of the neurocognitive data from 
CATIE are described at length elsewhere (Keefe, Mohs et al. 2003; Keefe, Bilder et al. 
Submitted). Briefly, this battery assessed aspects of neurocognitive function that are robustly 
associated with schizophrenia, that could plausibly improve with treatment, and which were 
practical to do in a large patient sample treated in “real world” clinical care settings 
distributed across the US. Despite minimal screening procedures, 91.2% of patients provided 
meaningful neurocognitive data at baseline entry into CATIE. There were 24 individual 
scores from 11 neurocognitive tests that were grouped into five domain scores (processing 
speed, reasoning, verbal memory, working memory, and vigilance). As detailed elsewhere 
(Keefe, Bilder et al. Submitted) and following the MATRICS factor model (Nuechterlein, 
Barch et al. 2004), a composite neurocognitive score (standardized average of the five 
domain scores) was determined to be a reasonable empirical summary of these data and was 
chosen a priori as the dependent analytic variable.  
We used multiple regression with stepwise selection to evaluate the multivariate 
correlates of the composite neurocognitive measure. Of a set of 16 potential covariates (none 
of which included genetic data), better composite neurocognitive scores were significantly 
associated with seven empirical covariates: higher scores on the reading subtest of the 
WRAT-3 (p<0.00005), lower PANSS negative symptom scale scores (p<0.00005), fewer 
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years since the age at which an antipsychotic was first prescribed (p<0.00005), younger age 
at CATIE baseline (p=0.0002), greater years of education (p=0.0002), the absence of a recent 
clinical exacerbation (p=0.002), and the absence of evidence of clinically significant drug use 
(p=0.01). These variables were used as covariates in adjusted analyses.  
Population stratification is a potential limitation of association studies (Risch 2000; 
Sullivan, Eaves et al. 2001) and is a salient concern in CATIE given its explicit intent to 
ascertain a diverse, clinically representative sample (Stroup, McEvoy et al. 2003; Lieberman, 
Stroup et al. 2005). Stratification effects are more likely with fewer strata and larger samples 
(Devlin and Roeder 1999; Wacholder, Rothman et al. 2000; Freedman, Reich et al. 2004). 
Some have argued that the threat of population stratification is exaggerated (Risch and Teng 
1998; Risch 2000) and that controlling for reported ancestry will reduce the risk (Devlin and 
Roeder 1999; Wacholder, Rothman et al. 2000). There are two preconditions for population 
stratification to yield false positive results (Gorroochurn, Hodge et al. 2004; Heiman, Hodge 
et al. 2004). Because population stratification as a confounder exists only if the phenotypic 
distribution and the marker allele frequency differ across ancestral strata, we will be able to 
determine the impact of stratification by measuring the marker and disease frequency and 
predict the extent of stratification. If there is substantial evidence that population substructure 
exists in the overall CATIE sample for the markers studied here, we default to stratified 
analysis. CATIE subjects were allowed to select multiple racial categories (White, 
Black/African-American, American Indian or Alaska native, Asian, Native Hawaiian or 
Pacific Islander, or Other) and were also asked if they were Hispanic or Latino. Inferred 
ancestry was defined as “Africa only” if a subject endorsed Black/African-American 
only,”Europe only” if a subject endorsed White only, and “Other” if any other racial category 
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was endorsed. Our rationale for use of inferred ancestry as an index of population 
stratification is described at length elsewhere (Shields, Fortun et al. 2005).  
Statistical Analysis. The logic underlying our analyses is explicated in the Results. 
Data management and statistical analyses were performed with SAS (version 9.1) (SAS 
Institute Inc. 2004). Significance testing and adjustment for multiple comparisons were via a 
permutation approach (Efron and Tibshirani 1993; Lazzeroni and Lange 1998; Good 2004). 
HaploView (version 3.2) (Barrett, Fry et al. 2004) was used to test Hardy-Weinberg 
Equilibrium (HWE) and |D’| and r2 linkage disequilibrium estimates (Devlin and Risch 
1995). Haplotype analyses were conducted with the R (version 2.1.1) (R Development Core 
Team 2005) function haplo.score (contained in version 1.2.0 of the haplo.stats library) 
(Schaid, Rowland et al. 2002).  
Project Context. All COMT SNPs genotyped are reported. Additional genes are under 
investigation (see http://www.med.unc.edu/~pfsulliv/downloads.htm for an updated list). We 
have attempted to follow published guidelines for association studies (Sullivan, Eaves et al. 
2001; Little, Bradley et al. 2002; Colhoun, McKeigue et al. 2003). 
 
Results 
 In this study, DNA samples from 641 CATIE participants were used.  Descriptive 
information for these subjects is detailed in Table 3.1.  In general, this population was 
intended to be diverse, with a chronic course of disease.  The people included in the CATIE 
study have suffered from schizophrenia for a long time, with a mean time since first 
antipsychotic prescribed of 14.16 years.  Of the 641 subjects, 450 (73.3%) are males and only 
168 are females.  
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 The region of chromosome 22q11.21 including COMT is depicted in Figure 3.1.  
Each of the 10 SNPs genotyped are noted, including the haplotype from Shifman et al. 
(Shifman, Bronstein et al. 2002) the Val158Met (rs4680) functional polymorphism, and the 
promoter SNP. 
 There are two reasons which may lead one to stratify by race to avoid false positives.  
The first is if the phenotypic distribution differs across strata.  Initially there did seem to be a 
difference in the phenotypic distribution of perseverative errors or neurocognitive composite 
score by inferred ancestry.  However, once the composite neurocognitive score or perseverate 
error score was adjusted for empirical covariates, there was no association with inferred 
ancestry.  The composite neurocognitive score was adjusted for seven empirical covariates 
which included the reading subtest of the WRAT-3, PANSS negative symptom scale scores, 
years since an antipsychotic was first prescribed, age, education, any recent exacerbation, and 
no clinically significant drug use.  The perseverative error score was adjusted for four 
empirical covariates including the reading subtest of the WRAT-3, PANSS negative 
symptom scale scores, years since an antipsychotic was first prescribed, and Calgary 
depression score.  Since the phenotypic difference seen between the inferred ancestry groups 
was eliminated after adjusting for the various covariates, the first reason to stratify by 
inferred ancestry is eliminated. 
 The second reason for possibly stratifying data is if there is an allele frequency 
difference across the strata.  HWE testing was performed for each SNP for all samples and 
by strata (Table 3.2).  Three SNPs were out of HWE when looking at the entire sample, 
however when looking at the allele frequencies for each of the three SNPs (rs740601, rs4680, 
rs165599), and testing for HWE for each SNP by inferred ancestry, all were in HWE.  Since 
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the phenotypic distribution across strata was not significantly different, association was 
tested without stratification.     
 Linkage disequilibrium testing was performed by strata, D’ and r2 values were 
calculated for each pair of SNPs.  Table 3.3 gives both values for each pair of SNPs.  Using 
the r2 values only shows that relatively few SNPs are in LD.  The SNPs chosen do not 
represent very good coverage of COMT, however it is the best to date. 
 Association of each SNP with each of the two phenotypes was assessed, the results 
are listed in Table 3.4.  For the WCST or perseverative errors, two SNPs (rs651892 and 
rs4680) were significantly associated at the 0.05 level, however once adjusting for multiple 
comparisons the association was not statistically significant.  Interestingly, the association 
with the functional SNP (rs4680), was opposite of what was previously reported by Egan et 
al (Egan, Goldberg et al. 2001).  In the previous study by Egan et al, the Met allele was found 
to enhance prefrontal cognition, while here we find it to impair.  
 Haplotype analysis was performed for each of the three haplotypes, two HapMap 
haplotypes and the haplotype identified by Shifman et al. (results not shown).  None of the 
SNPs or haplotypes were found to be significantly associated with either composite 
neurocognitive score or perseverative error score. 
 
DISCUSSION 
 The initial hypothesis of this study, which was designed in 2004, was that rs4680 
would be significantly associated with score on the WCST (perseverative error).  In addition, 
it was thought that the Met allele would enhance performance and the Val allele would 
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impair performance on this test, since this is what was previously reported (Egan, Goldberg 
et al. 2001).  In this study however, no significant association was found, and better 
performance on the WCST tended to correlate with Val allele.  Then two HapMap 
haplotypes, and a haplotype from Shifman et al.(Shifman, Bronstein et al. 2002) were added 
in addition to a promoter SNP.  None were found to significantly associate with WCST 
score, even when stratified by sex.  The composite neurocognitive score was then added to 
the analysis, and again no association was observed.  
 These results represent the largest study to date for association of COMT genotypes 
with perseverative error score or composite neurocognitive score.  While no association was 
observed, this does not mean that COMT is not involved in predisposition to schizophrenia.  
It simply means that the markers which were genotyped, and those in LD with those markers 
may not be involved in neurocognition.  While this is the largest number of SNPs to be 
genotyped in COMT, it does not represent full gene coverage, which would require at least 
twenty more SNPs, so a SNP which is associated with the neurocognitive phenotype may 
have been missed.  This study was designed before the most recent HapMap information was 
available.  Now that more information is available, future studies could be designed with 
better coverage of COMT. 
 Since this study was designed, there have been other negative association studies of 
COMT with the WCST (Mills, Langley et al. 2004; Taerk, Grizenko et al. 2004).  It is 
possible that the previous finding of association was a false positive, or that performance on 
the WCST varies and the subjects in the CATIE trial were only assessed once.  It is also 
important to note that in this study an endophenotype is being measured rather than the 
presence or absence of schizophrenia, so COMT may still be involved in some other aspect 
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of the disease not related to neurocognition.  Further studies are necessary including case-
control association studies, and the CATIE sample is an excellent population to perform 
future analyses. 
 All of the statistical analysis mentioned in this chapter was performed by Patrick F. 
Sullivan.  I performed all molecular analysis, organized samples, performed all genotyping 
and genotyping quality control. 
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Figure 3.1:  Depiction of the chromosome 22q11 region containing COMT. The top five 
lines give general information about COMT. After the base tick marks, the positions of three 
TXNRD2 isoforms, two COMT isoforms, and ARVCF are shown. For each gene, the direction 
of transcription is indicated by > (5’ ? 3’) or < (5’ ? 3’), exons are vertical bars, and “U” 
indicates the presence of an untranslated region. The positions of HapMap SNPs with minor 
allele frequencies ≥5% are shown along with four haplotype blocks identified from HapMap 
genotypes from Caucasians. Finally, the figure shows the positions of rs4680 (encoding the 
MB-COMT val158met polymorphism), the three-SNP haplotype studied by Shifman et al. 
(Shifman, Bronstein et al. 2002), a SNP in the MB-COMT P2 promoter (Palmatier, Pakstis et 
al. 2004), and the 10 SNPs genotyped in this investigation. All data are from 
http://genome.ucsc.edu (hg16) and http://hapmap.org (release #11, 9/04). 
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Table 3.1:  Descriptive data for CATIE subjects 1.  
Continuous variables Mean SD Median IQR Range 
Age in years 40.7 11.1 42 33, 49 18, 67 
Years since first antipsychotic prescribed 14.1 10.6 13 4, 22 0, 56 
Years of formal education 12.2 2.2 12 11, 13 3, 21 
Clinician global severity score 3.9 1.0 4 3, 4 1, 7 
PANSS total score 73.1 17.5 73 61, 85 33, 132 
PANSS positive symptom score 17.8 5.6 18 14, 22 7, 36 
PANSS negative symptom score 19.7 6.5 20 15, 24 7, 41 
WCST perseverative errors2 0.0 1.0 0.31 -0.42 0.66 
Neurocognitive composite score2 0.0 0.9 0.02 -0.63 0.63 
Nominal variables Number Percent    
Male gender 450 73.3%    
Inferred continental ancestry 
 Africa only 
 Europe only 
 Other 
 
177 
365 
72 
 
28.8% 
59.4% 
11.7% 
   
Married or with significant other 64 10.4%    
Current employment, full or part-time 39 6.4%    
Hospitalized/received crisis treatment in prior 3 
months 158 25.7% 
   
First language is English 574 93.5%    
Lifetime drug/alcohol abuse or dependence 
(SCID) 281 45.8% 
   
Current drug/alcohol abuse or dependence 
(SCID, clinician, or hair toxicology) 183 29.8% 
   
 
1 Abbreviations. SD=standard deviation. IQR=interquartile range, p25-p75. WCST=Wisconsin Card Sorting Test.  
2 Directionality: greater scores mean better performance.  
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Table 3.2:  CATIE allele frequency data for 10 SNPs in COMT.  
Chr. 22 Locus Inferred  HWE Allele 1 Allele 2 
Position (rationale) Ancestry N χ2 P value Base Freq. Base Freq. 
18,301,700 Rs6518592 Entire sample 695 1.02 Ns A 0.37 C 0.63 
 (htSNP, block 1) European only 395 0.00 Ns  0.42  0.58 
  African only 208 2.66 Ns  0.27  0.73 
  Other 92 0.29 Ns  0.36  0.64 
18,302,646 Rs2097603 Entire sample 696 0.07 Ns A 0.60 G 0.40 
 (P2 promoter) European only 395 0.16 Ns  0.58  0.42 
  African only 209 0.27 Ns  0.64  0.36 
  Other 92 0.74 Ns  0.63  0.38 
18,303,438 Rs2020917 Entire sample 696 0.43 Ns C 0.76 T 0.24 
 (htSNP, block 1) European only 395 0.11 Ns  0.69  0.31 
  African only 209 0.93 Ns  0.89  0.11 
  Other 92 0.01 Ns  0.77  0.23 
18,304,675 Rs737865 Entire sample 693 0.77 Ns A 0.75 G 0.25 
 (Shifman/Bray) European only 393 0.10 Ns  0.70  0.30 
  African only 208 0.88 Ns  0.86  0.14 
  Other 92 0.08 Ns  0.76  0.24 
18,319,731 Rs740603 Entire sample 695 0.61 Ns A 0.51 G 0.49 
 (htSNP, block 1) European only 394 0.45 Ns  0.48  0.52 
  African only 209 0.00 Ns  0.54  0.46 
  Other 92 0.10 Ns  0.59  0.41 
18,325,317 Rs740601 Entire sample 696 5.17 0.02 A 0.62 C 0.38 
 (htSNP, block 2) European only 395 3.27 0.07  0.62  0.38 
  African only 209 2.57 0.11  0.57  0.43 
  Other 92 0.48 0.49  0.72  0.28 
18,325,825 Rs4680 Entire sample 692 4.71 0.03 A 0.46 G 0.54 
 (htSNP, block 2,  European only 392 2.66 0.10  0.53  0.47 
 Val158met) African only 208 1.18 0.28  0.31  0.69 
  Other 92 2.62 0.11  0.44  0.56 
18,326,686 Rs4646316 Entire sample 695 0.11 Ns C 0.80 T 0.20 
 (htSNP, block 2) European only 394 0.21 Ns  0.79  0.21 
  African only 209 0.80 Ns  0.80  0.20 
  Other 92 0.46 Ns  0.82  0.18 
18,327,115 Rs165774 Entire sample 694 3.85 Ns A 0.29 G 0.71 
 (htSNP, block 2) European only 393 2.04 Ns  0.35  0.65 
  African only 209 0.02 Ns  0.22  0.78 
  Other 92 0.16 Ns  0.22  0.78 
18,331,335 Rs165599 Entire sample 696 10.58 0.001 C 0.44 T 0.56 
 (Shifman/Bray) European only 395 0.02 0.88  0.29  0.71 
  African only 209 1.51 0.22  0.68  0.32 
  Other 92 2.06 0.15  0.47  0.53 
 
Het=heterozygosity, HWE=Hardy-Weinberg equilibrium, Ns= Not significant at 0.05 level
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 Table 3.3:  Patterns of linkage disequilibrium within COMT by inferred ancestry.  
African 
only rs6518592 rs2097603 rs2020917 rs737865 rs740603 rs740601 rs4680 rs4646316 rs165774 rs165599 
Rs6518592  0.62 0.04 0.06 0.23 0.01 0.07 0.01 0.01 0.00 
Rs2097603 0.97  0.07 0.06 0.17 0.00 0.02 0.02 0.00 0.00 
Rs2020917 1.00 1.00  0.68 0.00 0.05 0.04 0.01 0.02 0.01 
Rs737865 1.00 0.82 1.00  0.01 0.03 0.05 0.01 0.02 0.00 
Rs740603 0.85 0.59 0.17 0.17  0.00 0.02 0.05 0.00 0.00 
Rs740601 0.15 0.10 0.54 0.39 0.04  0.25 0.07 0.14 0.03 
Rs4680 0.30 0.17 0.83 0.81 0.24 0.86  0.10 0.60 0.19 
Rs4646316 0.30 0.39 0.11 0.12 0.44 0.45 0.93  0.07 0.00 
Rs165774 0.10 0.03 0.77 0.71 0.14 0.82 1.00 1.00  0.29 
Rs165599 0.06 0.01 0.14 0.14 0.00 0.31 0.43 0.09 0.70  
           
European 
only rs6518592 rs2097603 rs2020917 rs737865 rs740603 rs740601 rs4680 rs4646316 rs165774 rs165599 
Rs6518592  0.98 0.32 0.31 0.54 0.14 0.17 0.03 0.05 0.03 
Rs2097603 0.99  0.32 0.31 0.55 0.14 0.17 0.03 0.05 0.04 
Rs2020917 1.00 1.00  0.97 0.26 0.40 0.29 0.11 0.14 0.03 
Rs737865 1.00 1.00 0.99  0.27 0.39 0.28 0.12 0.14 0.03 
Rs740603 0.84 0.84 0.80 0.82  0.28 0.23 0.05 0.09 0.03 
Rs740601 0.56 0.55 0.75 0.75 0.70  0.71 0.31 0.34 0.05 
Rs4680 0.53 0.52 0.75 0.75 0.54 0.99  0.20 0.46 0.21 
Rs4646316 0.39 0.39 0.44 0.44 0.46 0.85 0.80  0.15 0.08 
Rs165774 0.25 0.24 0.76 0.75 0.39 0.99 0.98 1.00  0.20 
Rs165599 0.34 0.35 0.17 0.17 0.28 0.28 0.66 0.83 0.92  
           
Other rs6518592 rs2097603 rs2020917 rs737865 rs740603 rs740601 rs4680 rs4646316 rs165774 rs165599 
Rs6518592  0.95 0.17 0.19 0.23 0.06 0.29 0.03 0.00 0.08 
Rs2097603 1.00  0.18 0.19 0.21 0.05 0.25 0.03 0.00 0.07 
Rs2020917 1.00 1.00  0.91 0.18 0.41 0.10 0.15 0.01 0.00 
Rs737865 1.00 1.00 1.00  0.15 0.39 0.12 0.19 0.01 0.00 
Rs740603 0.76 0.72 0.64 0.57  0.21 0.03 0.08 0.02 0.01 
Rs740601 0.53 0.45 0.74 0.69 0.60  0.31 0.40 0.11 0.00 
Rs4680 0.64 0.58 0.67 0.69 0.24 1.00  0.17 0.35 0.28 
Rs4646316 0.46 0.45 0.46 0.53 0.49 0.85 1.00  0.06 0.03 
Rs165774 0.10 0.06 0.32 0.34 0.20 1.00 1.00 1.00  0.15 
Rs165599 0.39 0.36 0.04 0.08 0.15 0.02 0.63 0.36 0.76  
 
Values below the diagonal are D’ and r2 above the diagonal. Areas of increased LD are highlighted. Outlined SNP names 
form haplotype blocks.  
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Table 3.4:  Single SNP results for phenotype-genotype associations.  
Phenotype SNP F P-value Genotypes Least square means 
Aim 1—WCST perseverative errors rs6518592 3.50 0.0309 AA AC CC -0.24 0.05 0.05 
 rs2097603 2.87 0.0575 AA AG GG 0.05 0.05 -0.20 
 rs2020917 0.97 0.3794 CC TC TT -0.03 0.08 0.10 
 rs737865 1.25 0.2859 AA AG GG -0.03 0.07 0.19 
 rs740603 1.90 0.1498 AA AG GG -0.10 0.08 0.02 
 rs740601 0.99 0.3724 AA AC CC -0.05 0.07 0.04 
 rs4680 4.17 0.0160 AA AG GG -0.18 0.10 0.00 
 rs4646316 0.19 0.8278 CC CT TT 0.00 0.04 -0.08 
 rs165774 0.10 0.9067 AA AG GG 0.06 0.02 0.00 
 rs165599 0.24 0.7834 CC CT TT 0.02 0.04 -0.03 
Aim2—Composite score rs6518592 0.16 0.8486 AA AC CC -0.02 0.00 0.01 
 rs2097603 0.17 0.8431 AA AG GG 0.02 0.00 -0.01 
 rs2020917 0.98 0.3756 CC TC TT -0.02 0.04 0.07 
 rs737865 1.27 0.2805 AA AG GG -0.02 0.04 0.07 
 rs740603 1.02 0.3603 AA AG GG -0.04 0.03 0.02 
 rs740601 0.56 0.5702 AA AC CC -0.02 0.03 -0.01 
 rs4680 1.28 0.2792 AA AG GG -0.05 0.03 0.00 
 rs4646316 0.22 0.8023 CC CT TT 0.00 0.01 0.07 
 rs165774 0.96 0.3847 AA AG GG 0.06 0.03 -0.02 
 rs165599 0.03 0.9737 CC CT TT 0.00 0.01 0.01 
Chapter 4 
Differential Allelic Expression of Candidate Genes For 
Schizophrenia 
Introduction 
 
Gene variants which lead to changes in gene expression, otherwise known as 
differential allelic expression (DAE) (Knight 2004), may ultimately result in predisposition 
to disease.  For instance, a specific allele of the adenomatous polyposis coli tumor suppressor 
gene (APC) decreases expression, and ultimately, foments predisposition to the development 
of familial adenomatous polyposis (FAP) (Yan, Dobbie et al. 2002).  Another example of the 
role of DAE in human diseases is obesity.  A T/G polymorphism in the adiponectin gene was 
reported to be associated with obesity (Stumvoll, Tschritter et al. 2002).  A recent study 
examined the expression of the two alleles in adipose tissue of heterozygotes (Yang, Tsou et 
al. 2003), and found that the allele associated with obesity showed higher expression.  These 
two examples suggest how DAE could play a role in predisposition to complex diseases.   
 Since many genes are thought to be involved in predisposition to schizophrenia, the 
study of DAE for the relevant candidate genes could prove to be a powerful tool.  To date, 
studies have focused predominantly on identifying polymorphisms which result in change in 
an amino acid sequence.  However, it is important to explore the role of non-coding as well 
as the coding polymorphisms when studying changes in gene expression.  In addition, one 
must also individually examine cis-elements or trans-acting factors as one might dilute the 
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signal from the other (Pastinen, Ge et al. 2005), in trying to identify both simultaneously.  In 
this chapter, we are principally interested in cis-elements that alter gene expression. 
 Several studies have addressed the question of whether there are differences in 
candidate gene expression between persons with and without schizophrenia (Bray, Buckland 
et al. 2003; Weickert, Straub et al. 2004).  In those studies, SNPs that lead to differential 
expression were assessed in relation to schizophrenia.  The role of one candidate gene 
(COMT) has been examined in the following three reports, however with inconsistent results.  
The first study by Bray et al. assessed COMT mRNA expression in post-mortem brains of 
individuals with and without schizophrenia (Bray, Buckland et al. 2003).  They found a 
significant decrease in COMT gene expression associated with a previously identified risk 
haplotype (rs737865-rs165599) (Shifman, Bronstein et al. 2002).  The second study by 
Tunbridge et al. looked at COMT mRNA levels in post-mortem brains from cases with 
schizophrenia and matched controls and found no difference in COMT mRNA abundance 
between cases and controls, nor did they find an association between mRNA level and 
COMT genotype (Tunbridge, Burnet et al. 2004).  The third study by Chen et al. examining 
COMT mRNA levels in cases with schizophrenia and controls found no difference in COMT 
expression, nor did it find an association of any SNP with differential expression (Chen, 
Lipska et al. 2004).  Chen et al. did, however, find a difference in COMT protein levels and 
activity.  These studies highlight the inconsistencies in DAE studies in humans with only one 
of the three studies finding differential COMT expression and SNPs that correlate with the 
difference in expression, while the two studies did not find a significant change in COMT 
expression. 
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 The inconsistent COMT expression findings in humans described above may be 
caused by a variety of factors, four possibilities follow.  First, tissue collection in humans 
presents challenges, because it is imperative to get all samples at the same stage of the 
disorder, at the same age, and with similar cause of death since gene expression may vary as 
a result of any of these factors.  Since brain tissue can generally only be collected after death 
in humans, different specimens would not necessarily be of the same age, cause of death and 
stage of disease.  Second, genetic background is a major problem in identifying variants that 
alter gene expression.  One issue with the genetic environment pertains to the difference 
between identifying cis-regulatory elements versus trans-acting factors.  A difference in gene 
expression can be due to a change in a cis-element or in a trans-acting factor neither of which 
are the same across all humans, and are therefore difficult to isolate (Pastinen, Ge et al. 
2005).  The third issue is causality.  In humans, where the genetic background is different, it 
is very difficult to distinguish cause (a SNP indeed causes DAE) from a confounding effect 
(an unmeasured causative SNP is in linkage disequilibrium (LD) with the measured SNP).  
The fourth issue pertains to environmental effects that are obviously nearly impossible to 
control for in humans.  Subjects studied generally come from various geographic locations, 
different familial backgrounds, and different environmental exposures any one of which 
could possibly influence gene expression.   
 When it is not simple to study a genetic process in humans, a logical step is to use a 
model organism like inbred mice as all of the difficulties described above could, in theory, be 
remedied.  In addition, mouse models provide the advantage that one could tightly control for 
environment, genetic background, and age, and eventually, even determine causality.  
However, even in mice, discerning the extent of cis- vs. trans-acting regulatory variation can 
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present difficulties.  As with humans, the issue of trans-acting factors or genetic environment 
could affect expression levels (Cowles, Hirschhorn et al. 2002).  One cannot simply quantify 
total gene expression at a locus in two mouse strains, and assume that any differences are due 
to a cis-acting elements.  All trans-acting factors that may act on the cis-element of interest 
need to be identical for each allele studied.  To overcome this difficulty F1s could be used.  
F1s are ideal because they carry each of the two alleles of interest within each cell, and all the 
trans-acting factors and environmental conditions are identical.    In theory, for each gene of 
interest, the level of expression of each parental allele would be quantified for each F1.  Then, 
F1s which show a difference in expression between the two alleles would be used to map the 
allele/s which cause the change in expression.  The steps necessary to complete this type of 
study are briefly enumerated below. 
1. Panel of mouse strains:  To achieve high mapping resolution a panel of mouse 
strains was selected.  A subset was used as a proof of concept.   
2. Generate F1s:  F1s were generated from the subset of the pannel. 
3. RNA extraction:  RNA was extracted from each tissue of interest.  These will be 
used to test for DAE.  
4. Quantification of DNA contamination:  The level of DNA contamination across 
the RNA samples was quantified.  DNA may produce a product of the same size 
as the product from RNA.  Adjusting for DNA contamination will allow us to 
determine how much product is produced from RNA alone. 
5. Assay design:  An assay for each gene of interest had to be designed, tested, and 
standardized.  For the assay to be used, it had to amplify equally across all 
parental strains, such that differences in expression are measured rather than the 
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efficiency of the PCR for an allele.  The linear range for each assay had to be 
determined.  The expression level should be assessed while the PCR is in its 
linear phase, before it has reached a plateau.  The reason for this is that the 
amplification of each of the alleles does not plateau at the same time, which 
means that while one allele is still being doubled the other will not, and the ratio 
will change.  While both are in the linear range, the ratio will be constant, and 
representative of the initial number of copies of each allele.    
6. Finally once an assay is ready, differential expression can be identified for each 
gene, and potentially causative SNP mapped.    
 The goal of this study was to create a set of RNA samples, standardize the steps to 
identifying differential expression, and to assess the presence or absence of differential 
expression of candidate genes in mouse brain samples. 
Materials and Methods 
Mouse Breeding 
Mice from the following inbred strains were used: C57BL/6J (B6), A/J, PERA/EiJ (PERA), 
PERC/EiJ (PERC), CAST/EiJ (CAST), DBA/2J (DBA), WSB/EiJ (WSB), PWD/PhJ 
(PWD), FVB/NJ (FVB), JF1/Ms (JF1), and RBA/Dn (RBA). All mice were purchased from 
The Jackson Laboratory (Bar Harbor, ME) with the exception of JF1/Ms which are 
maintained by Dr. Terry Magnuson at the University of North Carolina at Chapel Hill (UNC-
CH).  Mice were housed and treated in compliance with the recommendations of the 
Institutional Animal Care and Use Committee (IACUC) of UNC-CH.  The following F1s 
were generated (dam always listed first and sire second) by Timothy A. Bell in the Pardo 
Manuel de Villena laboratory at UNC-CH:  (B6 x A/J) F1, (B6 x PERA) F1, (CAST x A/J) 
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F1, (DBA x B6) F1, (PERA x B6) F1, (PERA x WSB) F1, (PWD x B6) F1, (WSB x B6) F1, 
(A/J x B6) F1, (B6 x PWD) F1, (B6 x WSB) F1, (FVB x B6) F1, (JF1 x B6) F1, (PWD x A/J) 
F1, (RBA x A/J) F1, (PERC x B6) F1, (A/J x CAST) F1, (FVB x PWD) F1.   
Mouse Dissection and RNA extraction 
Mice were at least 3 months of age prior to harvesting tissues.  We extracted RNA from six 
F1s from every cross (3 males and 3 females).  All mice were anesthetized using isoflurane 
(Halocarbon Laboratories, North Augusta, SC), and killed by cervical dislocation.  Tissues 
dissected were brain, cerebellum, heart, lung, colon, liver, kidney, pancreas, testis/ovaries, 
and spleen.  Tissues except for pancreas were placed in TRIzol reagent (Invitrogen, Carlsbad, 
CA) for same day extraction or, for future extraction, in RNAlater (Qiagen, Valencia, CA) 
and stored at -80ºC. One 3 mm TissueLyser (Qiagen, Valencia, CA) bead was added to each 
sample and placed in the TissueLyser (Qiagen, Valencia, CA) for 5 minutes at 30 Hz at room 
temperature.  RNA was extracted according to the manufacturer’s instructions, and 
quantified using a spectrophotometer.  For RNA extraction from pancreas, a small piece of 
the pancrease was placed in a tube containing 600ul of RLT buffer (with B-mercapto 
ethanol) (Qiagen, Valencia, CA), and homogenized using the PowerGen 125 (Fisher 
scientific,Pittsburgh, PA).  Following homogenization, Qiagen RNeasy Mini Protocol for 
Isolation of Total RNA from Animal Tissues (Qiagen, Valencia, CA) was used.  After 
extraction, samples with a 260/280 reading of less than 1.65 failed quality control and were 
reextracted using the TRIzol protocol.  One hundred micrograms of RNA from samples that 
passed quality control were then cleaned up using the RNeasy mini protocol for RNA 
cleanup (Qiagen, Valencia, CA), including the optional Dnase step.  Samples were then 
quantified using a spectrophotometer, and assessed using the RNA 6000 nano assay (Agilent 
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Technologies, Palo Alto, CA) on the Bioanalyzer 2100 (Agilent Technologies, Palo Alto, 
CA).  Samples that did not pass quality control after being run on the Bioanalyzer were 
discarded. 
DNA Extraction 
Parental DNAs were purchased from The Jackson Laboratory (Bar Harbor, ME).  F1 DNAs 
were extracted from either tail or liver biopsy using the GenElute™ Mammalian Genomic 
DNA Miniprep Kit (Sigma, St.Louis, MO) according to the manufacturers’ 
recommendations. 
 
Assay Design 
Primer design 
Primers were designed for both Aldoa and Prodh.  An important feature of an amplicon is 
that it contains polymorphisms between the strains.  If there are no variants between parental 
strains, it is impossible to determine which product is from which parent.  In addition, primer 
binding sites had to be identical across all strains which would be tested with that assay.  If 
the primers do not bind equally to all the strains tested, then the difference in the quantity of 
product could be simply due to differences in primer binding rather than differences in the 
quantity of template.  Ideally, primers would also span an intron, so that when amplifying 
from RNA, any DNA contamination in the sample would not contribute to the signal.  When 
primers could not meet all of these criteria including that they be intron spanning, non-intron 
spanning primers were used and the expected amount of DNA contamination was subtracted.  
The primers designed for Aldoa and Prodh follow: 
Aldoa:   F: 5’ ACTTGAAGCGCTGCCAGTATGTT 3’  
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  R: 5’ GTCACAGCACTTCGTCGCACAGTGCC 3’  
Prodh:  F: 5’ TGATGGAGGTACTCCCTTACCTGT 3’  
  R: 5’ AAACAGGCTTCCTAGTCTGTCCTC 3’ 
 The Aldoa forward primer binding site is in exon 6 and the reverse primer is located 
in exon 7; together, the primer set spans intron 6-7 which is only 92bp long.  The advantage 
of a small intron is that in addition to amplification from RNA, PCR from DNA is also 
possible.  This ability to amplify from both allows one to test primer binding in DNA across 
species, which is not possible to do from RNA.  The expected product sizes are 180bp or 
272bp from an RNA or DNA template respectively, which can be easily distinguished by gel 
electrophoresis.  In addition Aldoa is widely expressed, and had been sequenced in all strains 
to be used in this study by the Pardo Manuel de Villena lab.  The availability of genomic 
sequence across all strain allows us to know for sure that there are no polymorphisms in the 
primer binding sites, and that the expected product sizes are not very different so they will be 
easily identified by gel electrophoresis.  For these reasons, Aldoa was used as a test gene for 
all standardization steps.    
 The Prodh primers are not intron-spanning.  The forward primer binding site is 
located in the last exon 14, and the reverse is located in the 3’UTR, and the total expected 
product size from DNA or RNA is 565bp.  The reason for selecting Prodh is that it is the 
smallest candidate gene, and that there was enough variation between the parental strains in 
that amplicon so that many F1s could potentially be tested for DAE.  The primer pairs were 
tested over DNA (B6 and F1) and RNA (F1), just to ensure that the primers work. 
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PCR/RT-PCR 
 All PCR and RT-PCR reactions were carried out using Eppendorf cMaster RTplusPCR 
System (Westbury, NY), and 32P labeled dCTP.  The manufacturers’ recommendations were 
followed with the exception of modified PCR conditions which follow:  
Aldoa: Annealing temp:68ºC, extension for 45 seconds, for 25 cycles.   
Prodh:  Annealing temp:68ºC, extension for 30 seconds, for 30 cycles 
Quantification:  All of the imaging data was collected using the Typhoon 9400 Variable 
Mode Imager (Amersham Biosciences, Piscataway, NJ).  Quantification was performed 
using the ImageQuant™ V 5.2 molecular dynamics software (Amersham Biosciences, 
Piscataway, NJ).  Local average was subtracted for background correction. 
Single Strand Conformation Polymorphism (SSCP): All Reactions were run on 
SSCP gels prepared using MDE gel solution (Cambrex, Baltimore, MD) according to the 
manufacturer’s instructions. 
Standardization 
The following standardization steps were required before assaying for DAE. These are 
essential experimental standardizations to ensure that any inference of DAE is accurate.   
Linear Range:  The first step in identifying DAE was to ensure that the PCR is in the 
linear phase – i.e., has not yet reached the plateau stage.  To identify the linear range of the 
PCR, different amounts of DNA were used as a template, and separated by gel 
electrophoresis (SSCP) and quantified.  The PCR conditions were systematically altered until 
plots of DNA mass vs. signal intensity were linear or nearly so.  DNA quantities ranged from 
2.5 ng to 200 ng.  All reactions were done in duplicate. 
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Equal amplification:  To ensure that a primer pair could amplify equally from all strains, 
DNA from all parental strains was amplified and quantified (as described above).  If there 
were any strains that showed significantly lower or higher amplification, they were either 
excluded from the panel for that gene or a new primer set was designed. 
DNA Quantification:  Whenever non-intron spanning primers were used, one concern is 
the level of background DNA contamination.  The level of DNA contamination following all 
RNA extraction steps was expected to be low according to the manufacturers’ information –  
for this reason, it was not reasonable to use a spectrophotometer to quantify DNA 
contamination.  To quantify the amount of DNA contamination, an intron-spanning primer 
pair for Aldoa was used in the RT-PCR reactions with varying quantities of starting material.  
Using a standard curve and the Typhoon imager, levels of DNA contamination in RNA 
samples were quantified, and the amount of DNA contamination across samples per 100 ng 
of RNA was determined.  
Results 
 
 RNA was extracted from three males and three females from each type of F1.  The F1 
RNA samples that passed quality control, were available for further experiments, they are 
listed in Table 4.1.  Prior to assessing the presence or absence of DAE for each gene, several 
standardization steps had to be performed.  First an assay had to be designed according to the 
criteria previously mentioned.  This involved designing primers and testing both with DNA 
and RNA templates.  Aldoa was chosen as a test gene for many reasons that are outlined in 
the assay design section.  Briefly, Aldoa was chosen as it is highly expressed in many tissues 
(including brain), and because of the availability of high-quality genomic sequence for the 
strains used in this experiment, intron-spanning primers that allow the differentiation 
40 
between PCR products made from a DNA template and those from an RNA template, and the 
size of RNA and DNA products could be easily resolved.   
Determination of the linear range:  The first step which all subsequent steps rely on is 
determination of the linear range of the PCR.  The purpose of this standardization step is to 
identify the number of cycles beyond which the PCR has reached a plateau; if the PCR has 
reached a plateau, the ratio of the alleles is not constant, and no longer represents the true 
ratio of the alleles.  To determine this range, different amounts B6 DNA were used to seed 
PCR reactions in combination with different numbers of PCR cycles.  Products were 
subjected to SSCP gel electrophoresis, the gel was dried and exposed to a phosphor screen, 
and signal intensity was measured using the Typhoon imager (Figures 4.1 and 4.2).  After 
correcting for background, signal intensities from each sample were plotted against the 
amount (ng) of template used, and the conditions that produced the regression line with the 
highest coefficient of correlation were considered the linear range.  This was done for Aldoa 
and Prodh (Figures 4.3 and 4.4).  The linear range for Aldoa and Prodh were determined to 
be 25 cycles and 0-25 ng template and 30 cycles and 0-30 ng template, respectively.   
Equal Amplification:  One of the concerns mentioned above was that of primer design.  
Since several different strains were used with a given set of primers, it was critical that the 
primers amplify all strains equally.  If primers were bound more efficiently to one parental 
strain RNA than another, it would appear that there is DAE, when in reality this is an artifact 
of difference in primer binding.  To test for this, DNA from all parental strains were 
amplified using a primer set, and the products were run on an SSCP gel and quantified.  In 
order for an F1 to be tested for DAE, both the parental strains had to amplify equally.  The 
equity of amplification was assessed for both Aldoa and Prodh. 
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DNA contamination:  One anticipated problem was the presence of DNA contamination 
in the RNA samples.  The goal of this step was to determine the remaining amount of DNA 
contamination following extensive RNA cleanup steps for brain samples.  This was done 
only using the Aldoa primers, because the amount of DNA contamination is a sample-
specific feature and would be identical for all primers tested on a sample. 
To accomplish this goal, the information from the linear range experiment was 
utilized for RT-PCR conditions.  A standard curve was generated using B6 DNA in the range 
previously determined, and various amounts (ng) of RNA were amplified.  The signal 
intensity from the Typhoon Imager for each band produced from DNA contamination was fit 
to the line generated by the standard, and the percent contamination (ng DNA/ng RNA) was 
plotted against the amount (ng) of RNA used (Figure 4.5).  However, because the DNA 
contamination was very low for the smaller amounts of RNA, the readings were thought to 
be unreliable.  For this reason the amount of contamination per 100 ng of RNA was 
determined based on the mode rather than the mean.  The resulting contamination equaled 4 
ng DNA per 100 ng RNA.  Therefore, subsequent experiments using RNA extracted from 
brain were assumed to have the same level of DNA contamination, and in order for a gene to 
be tested for DAE the level of expression will have to be much higher than the equivalent of 
4 ng of DNA.  
Differential Allelic Expression:  Following extensive standardization and optimization, 
DAE was assessed.  Since Aldoa—a gene used for standardization—was of no interest to our 
study of genes relevant to schizophrenia, it was not tested for DAE.  The only other gene that 
had been assessed for linear range and equal amplification aside from Aldoa in the brain was 
Prodh.  To begin testing for DAE, one has to determine how much RNA template is to be 
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used in order to be within the linear range.  Several different amounts of RNA were tested in 
relation to the standard curve (Figure 4.6).  However, for Prodh, the expression was lower 
than what is expected for background from DNA contamination. 
 
Conclusion: 
In this study several goals have been completed.  The first aim was to create a set of 
F1 RNA samples to be used to study DAE.  For all F1s generated to date RNA samples from 
various tissues are available.  These RNAs will serve as a tool for many future studies in the 
Pardo Manuel de Villena, Mohlke, and Sullivan labs.  The second aim was to identify and 
standardize the steps necessary prior to testing for DAE.  The steps required have been 
identified.  They include the determination of the linear range of a PCR, level of DNA 
contamination, and equal amplification.  For both the Aldoa and Prodh assays the linear 
range was determined.  Expected DNA contamination across brain RNA samples was 
determined using the Aldoa assay.  In addition both the Aldoa and Prodh assays were found 
to amplify equally from all parental strains.  The final aim of this study was to assess the 
presence or absence of DAE of candidate genes.  PRODH was the only gene tested for DAE, 
however its expression in brain was so low that differential expression could not be 
determined. 
This study has laid the ground work for future experiments to assess DAE further.  
Necessary standardization steps including determination of the linear range, DNA 
contamination and equal amplification have been developed.  While no genes were 
successfully tested for DAE, significant amount of knowledge on identifying DAE has been 
gained, and these samples and tools are available for on-going and future studies. 
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Selection of the panel of F1s and experimental design was completed by Fernando 
Pardo Manuel de Villena.  All of the F1s were generated by Timothy A. Bell in the Pardo 
Manuel de Villena lab.  All RNA samples from pancreas were extracted by Li Qin in the 
Mohlke lab.   I extracted brain and cerebellum RNAs, and completed all the standardization 
steps. 
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Figure 4.1 
 
 
 
Figure 4.1:  Aldoa Linear Range: A. 25-cycle PCR seeded with 0-200 ng B6 DNA.  C. 
Replicate PCR of A.  B. The first eight samples from a and c reloaded in the 
following order: 0a, 0c, 2.5a, 2.5c, 5a, 5c, 10a, 10c, 15a, 15c, 20a, 20c, 25a, 25c, 50a, 
50c. D. 30-cycle PCR seeded with 0-200ng B6 DNA. F. Replicate PCR of D. in the 
same order.  E. The first five samples from D and F reloaded in the following order: 
0d, 0f, 2.5d, 2.5f, 5d, 5f, 10d, 10f, 15d, 15f.  The black triangles show increasing 
quantity of DNA used to seed the reactions. 
E. F. 
A B C
D
25 Cycles 
30 Cycles 
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Figure 4.2 
 
Figure 4.2:  Prodh Linear Range: A. 30-cycle PCR seeded with 0-50ng B6 DNA.  B. 
Replicate PCR of A. in the same order.  The black triangles show increasing quantity 
of DNA used to seed the reactions. 
A B
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Figure 4.3 
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Figure 4.3:  Graph of Aldoa Linear Range:  A. Band intensities from the gels were 
quantified using a Typhoon imager, and plotted against the starting amount (ng) of 
DNA B. A plot of the average for each quantity of template, with the line of best fit.  
Following optimization experiments, 25 PCR cycles and 0 to 25 ng were determined 
to yield products in the linear phase of the PCR for this primer pair. 
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Figure 4.4 
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Figure 4.4:  Graph of Prodh Linear Range:  A. All points for 30 cycles.  B. A plot of the 
average for each quantity of template, with the linear line of best fit.  30 cycles and 0 
to 30 ng was determined to be the linear phase of the PCR for this primer pair. 
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Figure 4.5 
A. 
 
B. 
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
0 20 40 60 80 100 120
ng RNA
%
 D
NA
 C
on
ta
m
in
at
io
n
 
 
 
 
DNA Contamination Standard Standard
A/JxCast 
Female 
A/JxB6 
Male 
A/JxB6 
Female 
A/JxCast 
Male 
49 
C. 
0
1
2
3
4
5
6
1 2 3 4 5 6 7
% Contamination
Co
un
t
 
 
Figure 4.5:  DNA Contamination:  A. Aldoa was used to determine the general amount of 
DNA contamination.  Two standard curves were run using 0 – 50ng DNA.  Quantity 
of DNA contamination was determined using 20, 40, 60, 80, or 100ng RNA from four 
different F1s.  B. Percent DNA contamination vs. quantity of RNA used to seed the 
reaction.  C. Percent DNA contamination plotted vs. the number of reactions that 
yield that quantity of contamination to determine the mode, which is about four 
percent or 4ng DNA per 100ng RNA.    The black triangles show increasing quantity 
of DNA or RNA used to seed the reactions. 
50 
Figure 4.6 
 
Figure 4.6:  PRODH Expression: A, B. A standard curve for Prodh was loaded in duplicate 
from 0-50 ng DNA.  C, D. One hundred to two hundred nanograms of F1 RNA was 
used to seed the RT-PCR reactions.  The total product is not more than what is 
expected to result from DNA contamination of about 4 ng DNA per 100 ng RNA, as 
can be seen in relation to the 5 ng band in the standard curve.  This leads to the 
conclusion that DAE cannot be tested in Prodh using this primer pair.    
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Table 4.1:  
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Male 3/3 1/3 3 3 3 3 3 3 3   A/J x B6 
Female 3/3 0/3 3 3 3 3 3 3 3   
Male 1/1 0/1        1/1 A/J x Cast 
Female 3/3 0/3        3/3 
Male 2/2 0/3 3 3 3 3 3 3/3 3   B6 x A/J 
Female 3/3 1/3 3 3 3 3 3 3/3 3   
Male 3/3 0/3 3 3 3 3 3 3 3   B6 x PWD 
Female            3/3 
Male 2/2 0/3 3 3 3 3 3 3 3 3/3 B6 x WSB 
Female 3/3 0/3 3 3 3 3 3 3 3 3/3 
Male 1/1 0/1 1 1 1 1 1 1 1   B6 x PERA 
Female 3/3 0/3 3 3 3 3 3 3 3   
Male 2/2 0/3 3 3 3 3 3 3/3 3   Cast x A/J 
Female 3/3 0/3 3 3 3 3 3 3/3 3   
Male 3/3 0/3 3 3 3 3 3 3/3 3 3/3 FVB x B6 
Female 3/3 0/3        3/3 
Male 3/3 0/3        3/3 FVB x PWD 
Female 3/3 0/3        3/3 
Male              JF1 x B6 
Female 1/1 0/1 1 1 1 1 1 1 1 1/1 
Male 3/3 0/3 3 3 3 3 3 3/3 3 3/3 PERA x B6 
Female 2/2 0/3 3 3 3 3 3 3/3 3 3/3 
Male 2/2 0/2 2 2 2 2 2 2/2 2 2/2 PERA x 
WSB Female 1/1 0/3 3 3 3 3 3 3/3 3 1/1 
Male 1/1 0/1        1/1 PERC x B6 
Female 3/3 0/3        3/3 
Male 2/2 0/2 2 2 2 2 2 2/2 2 3/3 PWD x A/J 
Female 3/3 0/3 3 3 3 3 3 3/3 3 3/3 
Male 3/3 0/3 3 3 3 3 3 3/3 3   PWD x B6 
Female 3/3 0/3 3 3 3 3 3 3/3 3   
Male            2/2 PWD x 
WSB Female              
Male 2/2 0/2 2 2 2 2 2 2/2 2 1/2 RBA x A/J 
Female 1/1 0/1 1 1 1 1 1 1/1 1 1/1 
Male 3/3 0/3 3 3 3 3 3 3 3   WSB x B6 
Female 3/3 0/3 3 3 3 3 3 3 3   
Male              WSB x 
PERC Female            2/2 
Table 4.1:  RNA samples available: All RNA samples which passed quality control are 
included in this table.  The ratios listed are the number of samples either tested for DNA 
contamination or used for other experiments out of the total available for each cross.  Whole 
numbers represent the total number of samples available, and are currently being updated. 
Chapter 5 
Conclusion 
 
 The studies discussed in this thesis are aimed to investigate genetic variation in 
candidate genes for schizophrenia research.  The goal of the study discussed in Chapter 2 
“Genotyping Accuracy for Whole-Genome Amplification of DNA from Buccal Epithelial 
Cells” was to determine if the GenomiPhi DNA Amplification Kit accurately amplified 
buccal cell DNA for various markers.  Several goals were accomplished.  Upon evaluation of 
the amplification kit using a rolling circle/Φ29 DNA polymerase, it was determined to be 
sufficiently accurate for the markers tested.  In future studies, markers would first need to be 
tested in both unamplified and amplified samples to determine accuracy for that region.  
While independent testing will be necessary for other markers, this work shows that the kit 
used performs better than other commercially available whole-genome amplification kits.  In 
the future it could be used to amplify samples for which very little DNA is available.  
 In Chapter 3, the goal was to determine the degree of association between genetic 
variation in COMT and neurocognition or working memory.   Chapter 3 of this work 
contained the largest case-only association study of COMT SNPs with neurocognition or 
working memory.  The results of this study suggest that COMT genotype alone is not related 
to neurocognition.  However the study was designed prior to the release of the most recent 
HapMap build.  Better SNP coverage of COMT may yield different results.  Lack of 
association also does not exclude association of COMT expression changes, methylation 
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pattern or other alterations with neurocognitive function.  This clearly requires further 
investigation.  SNPs in other candidate genes described in Chapter 1 (AKT1, DISC1/DISC2, 
SLC6A3, DRD3, DTNBP1, NRG1, PRODH, RGS4, and SLC5A4) will also need to be 
genotyped and tested for association with neurocognition.  In addition, multiple gene 
interactions should be assessed in relation to neurocognitive phenotype since multiple genes 
could have small main effects individually, but a large combined effect.  Appropriate 
controls should also be included in future studies. 
 In Chapter 4, an attempt was made to identify differential expression of candidate 
genes for schizophrenia.  An approach to studying differential expression of candidate genes 
was detailed.  The process by which DAE can be determined was elucidated, and the 
standardization steps were performed for two genes, Aldoa and Prodh.  No genes were 
actually found to exhibit differential expression in mouse brain.  The method outlined in 
Chapter 4, can prove be a very powerful tool in identification of differential expression and 
in the determination of the alleles responsible for the changes in expression. These 
experiments and the standardization protocols established here will facilitate DAE 
assessment for other candidate genes listed above, and in Chapter 1.  In addition these 
samples are likely to prove valuable for many other studies.  
 The studies discussed in this thesis have laid the groundwork for future experiments 
studying the genetics of schizophrenia.  
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